Optimizing Gastroenterology Naviguard Prior Authorizations

Klivira empowers gastroenterology practices to efficiently manage prior authorizations, specifically addressing the complexities of Naviguard's utilization management requirements.

For revenue cycle directors and prior authorization coordinators in gastroenterology, navigating utilization management programs like Naviguard presents unique challenges. High-volume biologics, advanced imaging, and complex procedures demand meticulous documentation and adherence to evolving payer policies, often leading to delays and denials.

Navigating Naviguard's Utilization Management in GI

Naviguard, as a UnitedHealthcare utilization management program, significantly influences prior authorization workflows for gastroenterology practices. It applies specific medical necessity criteria to high-cost treatments and procedures, requiring robust documentation from initial submission through re-authorization. Klivira streamlines this process, ensuring GI providers meet Naviguard's specific demands for biologics, advanced imaging, and complex endoscopic procedures.

Key Gastroenterology PA Triggers under Naviguard

IBD Biologics (e.g., Humira, Stelara, Skyrizi, Entyvio, Xeljanz)
Hepatitis C Direct-Acting Antivirals (e.g., Epclusa, Mavyret)
Advanced Abdominal Imaging (e.g., MRCP, MR enterography, CT enterography)
Specific Endoscopic Procedures (e.g., capsule endoscopy, ERCP, EUS)
Specialty Drugs for Functional GI Disorders (e.g., Viberzi, Motegrity, Linzess)
Non-routine Colonoscopy Screening Exceptions

Meeting Naviguard's Documentation Standards for GI Care

Naviguard's UM policies for gastroenterology frequently align with established clinical guidelines from bodies like ACG, AGA, and AASLD. This necessitates detailed documentation for conditions like IBD, including disease severity (Mayo score, CDAI), prior conventional therapy trials, and pre-initiation screenings. For Hepatitis C DAAs, genotype and fibrosis stage are critical, while advanced imaging requires clear clinical justification. Klivira's platform guides staff to capture these specific data points efficiently.

Common Naviguard Denial Drivers in Gastroenterology

Non-adherence to step therapy protocols for IBD biologics (e.g., requiring biosimilar trial).
Insufficient documentation of disease severity (e.g., missing Mayo score or CDAI).
Gaps in pre-treatment screening records (e.g., TB, hepatitis status).
Incomplete fibrosis stage or genotype documentation for Hepatitis C DAAs.
Lack of clinical correlation or prior workup for advanced imaging or capsule endoscopy.

Klivira's Automated Approach to Gastroenterology Naviguard PAs

Klivira directly addresses the operational complexities of gastroenterology prior authorizations under Naviguard by automating data extraction and submission. Our system incorporates ACG/AGA-guideline-aware logic for IBD biologic sequencing, automates treatment-status classification from EMR data, and supports comprehensive Hep C DAA workflows. This ensures accurate, complete submissions aligned with Naviguard's specific criteria.

Streamlining Chronic Care and Benefit Management with Naviguard

Gastroenterology often involves chronic conditions like IBD, requiring periodic re-authorization of biologics. Klivira manages these recurring PA cycles, proactively prompting for necessary documentation. Additionally, our platform assists in navigating the medical versus pharmacy benefit split for IBD biologics, a common workflow constraint that can complicate Naviguard submissions depending on the mode of administration.

Frequently asked questions

How does Klivira handle step therapy requirements for GI biologics with Naviguard?

Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic, which helps ensure that prior authorization requests for IBD biologics submitted to Naviguard meet their specific sequencing requirements, including conventional therapy trials or biosimilar preferences, reducing denial rates.

Can Klivira help with re-authorizations for chronic GI conditions managed by Naviguard?

Yes, Klivira is designed to manage periodic re-authorization workflows for chronic treatments common in gastroenterology, such as IBD biologics. Our system tracks re-authorization cadences and prompts for updated clinical documentation required by Naviguard for continuous approval.

Does Klivira integrate with our EMR to gather GI clinical data for Naviguard submissions?

Klivira offers robust EMR integration capabilities, allowing for automated extraction of relevant clinical data, medication histories, and diagnostic results directly from your system. This significantly reduces manual data entry for Naviguard prior authorization submissions, improving accuracy and efficiency.

What specific GI procedures or drugs are most impacted by Naviguard's UM?

In gastroenterology, Naviguard's utilization management most frequently impacts high-cost IBD biologics (e.g., Humira, Stelara, Skyrizi), Hepatitis C DAAs, advanced imaging (e.g., MR enterography), and specific endoscopic procedures like capsule endoscopy. These categories often require detailed clinical justification.

How does Klivira manage the medical vs. pharmacy benefit split for GI biologics under Naviguard?

Klivira's platform is equipped to handle the complexities of medical versus pharmacy benefit routing for biologic agents. This capability ensures that prior authorization requests for IBD biologics are correctly submitted to Naviguard based on the administration mode, whether provider-administered infusion or self-administered injection.